Clinical trial
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
NCT06563999
Study timeline
Study start (actual)2024-11-01Date precision: day
Registry last updated2026-04-21
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Lung Cancer Stage IIIunresolved
Mutationunresolved
Interventions
SunvozertinibDRUG · verified · RxNorm: sunvozertinib
CrizotinibDRUG · verified · RxNorm: crizotinib
PralsetinibDRUG · verified · RxNorm: pralsetinib
LarotrectinibDRUG · verified · RxNorm: larotrectinib
SavolitinibDRUG
PyrotinibDRUG
GlecirasibDRUG
EnsartinibDRUG · verified · RxNorm: ensartinib
Sponsors & collaborators
Sun Yat-sen Universitylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06563999 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.